Benjamin Parsons, DO
Hematology & Oncology · la Crosse, WINPI 1164688834
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $47,459 of the $61,741 with a category attached, or 76.9%. 15 manufacturers reported payments, led by Amgen at 57.7% of the total. Reporting peaked in 2019 at $48,037 and has fallen 99.6% since, to $174 in 2025. Among hematology & oncology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 76 payments — averaging $812.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$36K
- Bristol Myers Squibb$17K
- AstraZeneca$6K
- Seagen Inc.$1K
- Genmab U.S., Inc.$716
- Adaptive Biotechnologies Corporation$316
- plus $1K from 9 others
Across 43 payments — averaging $26,596 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$472K
- AstraZeneca$416K
- Beone Medicines Ltd.$126K
- Janssen Research & Development, LLC$40K
- Puma Biotechnology, Inc.$30K
- Bristol Myers Squibb$22K
- plus $39K from 5 others
What the payments were for
- Consulting fees$6,58511%
- Speaking & faculty fees$47,45977%
- Travel & lodging$4,1727%
- Food & beverage$3,4496%
- Education$760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 30 | $35,610 |
| Bristol Myers Squibb | 14 | $17,070 |
| AstraZeneca | 7 | $5,710 |
| Seagen Inc. | 1 | $1,225 |
| Genmab U.S., Inc. | 9 | $716 |
| Adaptive Biotechnologies Corporation | 3 | $316 |
| AVEO Pharmaceuticals, Inc. | 1 | $238 |
| Foundation Medicine, Inc. | 1 | $229 |
| Pfizer | 4 | $219 |
| Exelixis Inc. | 1 | $157 |
| E.r. Squibb & Sons, L.L.C. | 1 | $98 |
| Tempus AI, Inc | 1 | $72 |
| Gilead | 1 | $51 |
| Janssen Scientific Affairs, LLC | 1 | $16 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,741 in reported general payments places this provider in the 90th percentile of 248 hematology & oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 60 | $1,004,088 |
| ImbruvicaIbrutinib | 38 | $836,692 |
| JakafiRuxolitinib Phosphate | 41 | $672,778 |
| PomalystPomalidomide | 19 | $405,155 |
| VenclextaVenetoclax | 27 | $259,602 |
| BrukinsaZanubrutinib | 15 | $212,877 |
| CalquenceAcalabrutinib Maleate | 12 | $180,252 |
| CabometyxCabozantinib S-Malate | 11 | $176,751 |
| EliquisApixaban | 32 | $27,713 |
| Tamoxifen Citrate | 57 | $2,669 |
| Acyclovir | 254 | $2,533 |
| Hydroxyurea | 86 | $2,376 |
| Anastrozole | 46 | $1,408 |
| Warfarin Sodium | 64 | $1,113 |
| Dexamethasone | 26 | $415 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $17,070 | $1,004,08860 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $98 | $405,15519 claims |
| AstraZenecaCalquence | $5,710 | $180,25212 claims |
| Exelixis Inc.Cabometyx | $157 | $176,75111 claims |
| PfizerEliquis | $219 | $27,71332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 248 hematology & oncology providers in Wisconsin.
Other hematology & oncology in la Crosse
- Reggie Thomesla Crosse$12K
- Parameswaran HariMilwaukee$1.3M
- Sayed Mehdi HamadaniMilwaukee$546K
- Binod DhakalMilwaukee$535K
- Deepak KilariMilwaukee$359K
- Ehab AtallahMilwaukee$344K
- Nirav ShahMilwaukee$207K
- Razelle KurzrockMilwaukee$199K
- Syed AbutalibMilwaukee$154K
- Patrick FoyMilwaukee$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.